Aspen Pharmacare Holdings Limited · JSE:APN
Aspen Pharmacare — H1 2009 Earnings Presentation
57 slides from Aspen Pharmacare's earnings presentation, December 2008
Slide 1: Aspen Pharmacare Holdings Limited Interim Results
Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008
Slide 2: Take a pill…
Take a pill… Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 2
Slide 3: Income statement re-analysed
Income statement re-analysed 6 months ended 6 months ended % 31 December 31 December Chang 2008 2007 e R'm R'm Revenue 91% Cost of sales 4,264 2,230 Gross profit (2,320) (1,177) 85% Net operating expenses 1,944 1,053 74% Profit on disposal of business (728) (418) EBITA 0 59 75% Amortisation 1,216 69
Slide 4: Segmental revenue
Segmental revenue 31 December 2008 31 December 2007 R4.3bn R2.2bn Intl Intl 45 21% % SA SA 55 79% % Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 4
Slide 5: Segmental EBITA
Segmental EBITA 31 December 2008 31 December 2007 R1.2bn R0.64bn Intl 16% Intl SA 52% 48% SA 84% Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 5
Slide 6: Analysis of revenue
Analysis of revenue 31 December 2008 31 December 2007 R4.3bn R2.2bn Global Rest of the Product Rest of the World World s 3% 7% 16% Asia Latin Pacific Americ 13% South a South Africa 10% Africa 80% 55% Asia Pacific East 11% Africa 5% Aspen Pharmacare Holdings Limited Interim Results for the six month
Slide 7: Average movement currency against USD
Average movement currency against USD for the six months ended 31 December 2008 6 month Percentage movement of Revenue Region Reporting currency against Earned in USD Currency Asia Pacific 14% Australian Dollars (29%) 13% Japanese Yen 17% 1% Sub-Saharan Africa 53% South African Rands (23%) 48% Kenya
Slide 8: EBITA margin comparison
EBITA margin comparison H1 EBITA% H2 2008 H1 2009 2008 South Africa 30% 26% 25% Internationa 22% 21% 33% l Total 29% 25% 29% Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 8
Slide 9: Funding costs
Funding costs 6 months ended 6 months ended 31 December 2008 31 December 2007 R'm R'm Interest paid (313) (159) Interest received 115 131 Net Interest (198) (28) Preference share dividend paid (21) (18) Preference share dividend received - 17 Net preference share flows (21) (1) Notional interest on
Slide 10: Abridged balance sheet
Abridged balance sheet 6 months ended 6 months ended 31 December 2007 31 December 2008 R'm R'm Assets Non-current assets 7,674 2,897 - Tangible fixed assets 2,290 1,070 - Goodwill 678 537 - Intangible assets 4,635 848 - Investment in associates 24 25 - Non-current assets 47 40 - Preference share inv
Slide 11: Funding raised by Aspen Global
Funding raised by Aspen Global Value – USD 385 million – USD 346 million for acquisition of Eltroxin, Imuran, Lanoxin and Zyloric from GSK – Balance of facility for further investments Repayment terms – Effective 10 October 2008 – 5-year amortising loan of USD 255 million with 1-year capital repayme
Slide 12: Key ratios
Key ratios 6 mths ended 6 mths ended Year ended 31 December 31 December 30 June 2008 2007 2008 Gross Margin % 47% 46% 46% EBITA% 29% 27% 29% Gearing 32% 38% 59% Net debt / EBITDA 0.9x 3.4x [1.5x ] 2.1x Net Interest cover 23x 16x 6x Return on shareholders equity (annualised) 39% 31% 42% Return on tot
Slide 13: Distribution of fund managers
Distribution of fund managers 31 December 2008 30 June 2008 2% 1% 11% 1%1% 11% 19% 19% 67% 68% Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 13
Slide 14: Private sector (per IMS December 2008)
South Africa Private sector (per IMS December 2008) Market Aspen Growth Growth Growth in Total Market 12% 24% Branded Market 11% 34% Generic Market 22% 25% OTC Market 9% 19% Key Growth Drivers Pricing Generic shift and acceptance Emerging middle class driving volume growth GEMS Paten
Slide 15: Total private market
South Africa Total private market 31 December 2008 R17.87 billion (31 December 2007 – TPM R16.0 billion) Generic R3.51bn (R2.8bn) Ethical R9.45bn (R8.7bn) OTC R4.91bn (R4.5bn) Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 15
Slide 16: Ethical / generic percentage split (Rand)
South Africa Ethical / generic percentage split MAT Rand market share (Sch 3-7) (per IMS December 2008) MAT GENERIC MAT ETHICAL 74.53 74.32 74.09 73.73 73.62 73.54 73.38 73.14 73.12 73.08 73.06 72.88 Percentage 25.47 25.68 25.91 26.27 26.38 26.46 26.62 26.86 26.88 26.92 26.94 27.12 Jan-08 Feb-08 Mar
Slide 17: Ethical / generic percentage split (Units)
South Africa Ethical / generic percentage split MAT Units market share (Sch 3-7) (per IMS December 2008) MAT GENERIC MAT ETHICAL 54.90 55.16 55.46 55.51 55.55 55.70 55.96 55.94 55.90 55.86 56.00 54.63 45.37 45.10 44.84 44.54 44.49 44.45 44.30 44.04 44.06 44.10 44.14 44.00 Percentage Jan-08 Feb-08 Ma
Slide 18: Total pharma market Rand shares
South Africa Total pharma market MAT Rand shares (per IMS December 2008) ASPEN ADCOCK INGRAM PFIZER SANOFI-AVENTIS NOVARTIS CIPLA GSK 14.0 13.09 12.63 12.72 12.84 13.07 13.05 13.03 13.03 12.09 12.30 12.54 11.84 11.89 11.88 11.88 11.92 11.97 11.94 11.92 11.98 12.02 11.94 11.89 12.01 12.0 11.72 11.61
Slide 19: Aspen Pharmacare total vs. total industry
South Africa Aspen Pharmacare total vs. total industry MAT Units and Rand market growth (per IMS December 2008) Total Industry Units Growth Aspen Total Units Growth Total Industry Value Growth Aspen Total Value Growth 30 25 25 24 24 23 23 23 22 20 20 20 18 16 16 19 19 18 18 18 17 15 16 16 16 15 14 P
Slide 20: Aspen in South Africa
Aspen in South Africa Aspen is the largest pharma company in South Africa: – Leadership position in both the public and private sectors Extended our market share in the private market: – Market share at its highest point Focus on manufacturing excellence: – Professionalism, credibility, affordabilit
Slide 21: Aspen in South Africa (cont.)
Aspen in South Africa (cont.) Margin contraction: – Depreciating rand – Shift in mix to higher value / lower margin ARVs in public sector – Price increases in both the public and private sector to provide relief Aspen has outperformed the market in total: – Aspen has achieved this in each individual
Slide 22: Private generic market
South Africa Private generic market MAT Rand shares (per IMS December 2008) Aspen Generics Adcock Cipla Novartis Daiichi Sankyo Servier Lupin 40 35.21 35.30 35.43 35.49 35.95 35.86 35.78 35.73 35.67 34.65 34.59 34.59 30 Percentage 20 14.78 15.10 15.42 14.60 14.51 14.14 14.02 13.98 14.00 14.13 14.24
Slide 23: Aspen generic vs. generic industry
South Africa Aspen generic vs. generic industry MAT Units and Rand market growth (per IMS December 2008) Industry Generic Units Growth Aspen Generic Units Growth Aspen Generic Value Growth Industry Generic Value Growth 30 28 28 28 28 27 27 27 26 26 25 25 25 25 25 25 25 24 24 23 25 23 23 24 24 24 24
Slide 24: Aspen in South Africa Private generic industry
Aspen in South Africa Private generic industry Aspen has extended its leadership position The ownership of competitors has changed: – Aside from Adcock Ingram, competitors are international: • Small local operators purchased or closed • Reflection of the increased capex required • Competitive pressu
Slide 25: Private generic industry (cont.)
Aspen in South Africa Private generic industry (cont.) We are working through the process with the regulators: – Commitment from both sides – Still many wrinkles, but Regulator now more pro-active and engaging – Aspen has a better understanding of process Never been an advocate of price controls, ho
Slide 26: Antiretrovirals - private sector market share
South Africa Antiretrovirals - private sector market share per company MAT Rand Value (per IMS December 2008) Aspen Merck GSK Abbott Enaleni BMS BI Roche Adcock Ranbaxy 60 50 40 Percentage 30 20 10 0 Jan-08 Feb-08 Mar-08 Apr-08 May-08 Jun-08 Jul-08 Aug-08 Sep-08 Oct-08 Nov-08 Dec-08 Aspen Pharmacare
Slide 27: Aspen Pharmacare OTC vs. OTC industry
South Africa Aspen Pharmacare OTC vs. OTC industry MAT Units and Rand market growth (per IMS December 2008) OTC UNITS GROWTH ASPEN OTC UNITS GROWTH OTC VALUE GROWTH ASPEN OTC GROWTH 20 19 18 18 16 15 16 15 15 13 Percentage 14 11 11 12 9 9 10 10 10 10 9 9 9 9 9 9 8 8 8 8 8 6 4 2 6 8 6 9 6 10 7 14 6 1
Slide 28: South Africa OTC business
South Africa OTC business Increased market share Significant volume increases: – New trend – Historic sector volume growth had been pedestrian Profitability pressure in OTC: – Rand effect / components etc. – Detrimental loss of high margin slimming business: • Battling to regain lost sales with new
Slide 29: South Africa Consumer business
South Africa Consumer business Unaffected by pricing legislation Infant Milk Formulas: – Core brands within consumer – Continue to over-perform – Aspen’s quality standards ensued that our brands were unscathed by the milk scares – Driven both volume and value growth in consumer sector Other core bra
Slide 30: South Africa Public sector
South Africa Public sector Aspen supplies billions of tablets to government Large fluctuations in this demand places operational stress on the business: – Joint tenders have become exclusive: • Experienced two year projected off takes within two months – When tendering next year need to take cogniza
Slide 31: Public sector - Antiretrovirals patients on Lamivudine
South Africa Public sector - Antiretrovirals Number of Patients on Aspen Lamivudine (80% market share) 500,000 450,000 400,000 350,000 300,000 Patients 250,000 200,000 150,000 100,000 50,000 0 0 5 0 5 0 6 0 6 0 6 0 6 0 7 0 7 0 7 0 7 0 8 0 8 0 8 0 8 20 20 20 20 20 20 20 20 20 20 20 20 20 20 ep ec ar
Slide 32: Analysis of South African business
Analysis of South African business December 2008 R2.33bn Exports 14% SA Base 86% Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 32
Slide 33: South Africa Summary and prospects
South Africa Summary and prospects Aspen enjoys growing market shares in all sectors: – Both public and private sector showing volume growths Price increases will provide relief: – Positive effects from both public and private to flow next half Generic sector is buoyant: – Competition intense Regula
Slide 34: Summary and prospects (cont.)
South Africa Summary and prospects (cont.) Aspen is the spine of the South African pharmaceutical industry We will continue to perform in this dynamic market Increased emphasis on our profitability: – Benefits should flow through in this half Traditionally our second half has: – More turnover and be
Slide 35: South Africa Operations
South Africa Operations Without our operations, our international aspirations would have stayed a dream Embarked on an ambitious programme of technology and process improvements five years ago: – Decrease process times – Improve GMP – Improve yields – Increase compliance – Decrease manual interventi
Slide 36: Operations (cont.)
South Africa Operations (cont.) Transfer of products from the heritage facility to OSD 2 start from June Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 36
Slide 37: Operations – OSD recovery history
South Africa Operations – OSD recovery history Continue to build on our skill base: – Showing tangible improvements – Output doubling year on year 12,000 2007A 2008A 2009A/F 10,000 8,000 Recoveries 6,000 4,000 2,000 - Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Aspen Pharmacare Holdings Limited
Slide 38: Sterile facility
South Africa Sterile facility Undergoing start up: – Media fills completed – Commence manufacture in April s – Sales to start in June: t e rile • Prestige S – Will be in excess of 1,5 million units per month Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008
Slide 39: International operations
International operations Now a larger contributor to operating income than South Africa: – Addition of exports would further skew the picture Realisation of strategic plan which began with the manufacturing and IP upgrades Distribution is divided into following key geographic regions: – Asia Pacific
Slide 40: Global products from GSK / Iroko - focus on implementation
International operations (cont.) Global products from GSK / Iroko - focus on implementation Complex process: – Requires meticulous planning Key focus areas: – Transfer of regulatory applications – Change of packaging in all territories – Establish distribution platforms – Transfer of manufacture – N
Slide 41: International operations: Expected financial outcomes
International operations (cont.) Expected financial outcomes Key outcomes vs our earlier expectations: – Sales higher than budget little denominated in dollars – Cost of sales anticipate savings in actives / conversion – Marketing & Sales / Distribution will be higher than current GSK charge
Slide 42: International operations: LATAM
International operations (cont.) LATAM Split into two regions: – Brazil – Spanish Latam Latam – sales (incl. Global products) Only Spanish Latam sales Other Spanish 28% Mexico Latam 51% 35% Venezuel a Brazil 21% 65% Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 Decemb
Slide 43: International operations: Brazil
International operations (cont.) BRAZIL Key areas: Understanding and consolidating the business acquired: – Focused primarily on hospital tenders Completion of Campos facility: – Needed given domestic preferences – All local approvals by March 2009 – International approvals to follow Driving future
Slide 44: International operations: Campos
International operations (cont.) Campos Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 44
Slide 45: The Brazil team
B r azi l t eam The Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 45
Slide 46: International operations (cont.): Brazil sales and pipeline
International operations (cont.) New management appointed to hospitals: Brazil Sales – Grown turnovers and profitabilities – Challenged by shifting currencies: • R$ / $ = 1.57 → 2.50 – New focus on private business Private 30% Pipeline: Hospital – Strong organic pipeline: 70% • Initially Strides bas
Slide 47: Aspen Australia
rab * A} in Peosnilic neople prac ts and technology
Slide 48: International operations: Asia Pacific
International operations (cont.) ASIA PACIFIC Established platform in Australia for the region: – Strong management – Created capacity in this structure to drive regional growth Shown 55% growth in sales: – New Zealand turnover now more than NZ$10 million – Achieved in spite of heavy legislative pre
Slide 49: Aspen rep performance overall up to Q4 2008
International operations (cont.) Aspen rep performance overall up to Q4 2008 ASPEN performance Industry performance 8.80 8.60 8.60 8.40 8.20 Average score 8.03 8.00 7.80 7.60 7.40 7.20 7.00 gh . Ing x GSK rtis S ilag n e th n ca ma va lvay disk ck ntis arm w CSL ed er r ie r ott ll y MSD lou e ove a
Slide 50: International operations: Asian distribution networks
International operations (cont.) Distribution networks throughout Asia being established: – Products acquired sold through networks by June 2009 – Actively seeking to increase product offerings through organic pipeline introduction – Complex regulatory channels easier to navigate given progress on r
Slide 51: Sub-Saharan African – Aspen Shelys
International operations (cont.) Sub-Saharan African – Aspen Shelys Strong brand presence in East Africa supported by an effective distribution network Manufacturing facilities in Dar-Es-Salaam and Nairobi: – Focus on attaining P.I.C. / W.H.O. qualification – Donor manufacturing opportunities Sales
Slide 52: Aspen Shelys revenue by territory and segment
International operations (cont.) Sub-Saharan African – Aspen Shelys revenue by territory by segment Tanzania Uganda Zambia Rx Products OTC Other Malawi Kenya 14 % 31 3% % 13% 64 69 % % 2% 4% Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 52
Slide 53: Aspen Shelys awards
International operations (cont.) Sub-Saharan African – Aspen Shelys awards Best Manufacturer of the year Chemical & Chemical Products Large Manufacturers Category Aspen Pharmacare Holdings Limited Interim Results for the six months ended 31 December 2008 53
Slide 54: Intellectual property to be licensed to GSK
International operations (cont.) Intellectual property to be licensed to GSK Process of co-ordinating the individual GSK regions: – Product selection – Technical / regulatory back up – Territory specific manufacturing anomalies Anticipate GSK will: – Select more than 100 molecules initially – Quarte
Slide 55: Prospects South Africa
Prospects South Africa Private Sector: – Pricing increases – Good volumes – Visibility on earnings – Currency exposure – Improved market shares across all sectors – Have registered over 30 products in 2008: • will drive 2009 sales Public Sector: – Rising volume – ARV patient numbers increasing – Err
Slide 56: New product pipeline
New product pipeline MAT Rand value of products launched in the last 24 months (per IMS December 2008) Aspen Pfizer Cipla Novartis Merck Adcock Zydus Cadila Sanofi-Aventis Bayer Merck2 BI Lupin J&J Austell 20 18 16 14 Percentage 12 10 8 6 4 2 0 Aspen Pharmacare Holdings Limited Interim Results for t
Slide 57: Prospects International operations
Prospects International operations Increased capacity and capabilities: – Support future turnover growth Predictability of earnings Good brand recognition Key personnel in place Branded generic strategy implemented: – Emerging market focus Heavy focus on implementation: – Trench warfare, but slowly
Aspen Pharmacare Holdings — H1 2009 Earnings Presentation on 6ix